Navigation Links
Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Date:12/3/2010

EAST HANOVER, N.J., Dec. 3, 2010 /PRNewswire/ -- A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free survival (PFS) in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs) (1,2).

The published results are from Medical Research Council (MRC) Myeloma IX, a large, randomized, Phase III clinical trial of nearly 2,000 patients with multiple myeloma (1). These results were initially reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, in June 2010.

At a median follow-up of 3.7 years, Zometa significantly reduced the risk for death by 16% (hazard ratio [HR] 0.842; 95% confidence interval [CI] 0.74-0.96; P=0.0118) and the relative risk for PFS events by 12% (HR 0.88; 0.80-0.98; P=0.0179) compared with oral clodronate. In addition to demonstrating superiority to clodronate on survival endpoints, Zometa was significantly superior to clodronate in the prevention of SREs associated with multiple myeloma, regardless of SRE history at baseline (1).

More than 750,000 cases of multiple myeloma are diagnosed each year worldwide, with a median overall survival of three to five years (3). Nearly 95% of advanced stage multiple myeloma patients have bone disease and half of them will experience SREs (e.g., pathologic fractures, radiation or surgery to bone, spinal cord compression) if not treated (4,5).

"As a hematologist who treats patients with multiple myeloma, the survival benefit demonstrated by Zometa in this study is very encouraging," said Professor Gareth Morgan, Head of Haemato-oncology at The Royal Marsden and The Institute of Cancer Research, UK and one of the study's lead in
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
4. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
5. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
6. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
7. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
10. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... Texas , July 31, 2014 Vermillion, Inc. ... and women,s health, will hold a conference call on Thursday, ... results for the second quarter ended June 30, 2014. Financial ... the call. Vermillion,s Chairman, President and CEO ... question and answer period. Date: Thursday, August 14, ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... HOFFMAN ESTATES, Ill., Jan. 24, 2012 Life Spine, a ... for the surgical treatment of spinal disorders, announced record revenues ... introductions in 2011. The record revenue reflects ... 2011. "This has been an outstanding year for Life Spine. ...
... 2012  LoneStar Heart Inc., based here, today announced that ... Maciejewski to the company,s board of directors. The new ... for LoneStar Heart; Frank Ahmann, the company,s president and ... of Vessix Vascular, Inc.; and Eric N. Olson, Ph.D., ...
Cached Medicine Technology:LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 3
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Zensah®, ... released their innovative compression elbow sleeve , designed ... elbow pain, in two new bright colors for summer. ... pink and blue. Made of innovative proprietary Zensah® fabric, ... wicking and odor-preventing fabric. It features a no-slip cuff ...
(Date:7/31/2014)... 31, 2014 To further educate the ... provide the following safety information regarding leaving children in ... can have deadly consequences. Because a child’s body can ... of adults, leaving children alone in a hot vehicle ... even death. , Statistics of Children Left Alone in ...
(Date:7/31/2014)... 2014 Most mommy blogs are simple ... purpose is to attract all mothers from all walks ... particular group; whether its high fashion or child rearing. ... everything on the Internet was so segmented. “I found ... particular topic and then search Google to get information ...
(Date:7/31/2014)... A chance meeting at last April’s ... country artist/writer-producer Jimmy Robbins to Etymotic Research and ... an innovator in hearing wellness solutions, and maker ... 2012, Etymotic’s Music•PRO® Electronic Earplugs have revolutionized hearing ... and restoring natural hearing when hearing is not ...
Breaking Medicine News(10 mins):Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2
... ultrasound and specially modified contrast agents may allow researchers ... to research published in the March issue of The ... The technique enables researchers to visualize tumor activity at ... be helpful for the early detection of disease," said ...
... If the behavior of the seasonal form of the ... are good that most strains of the pandemic H1N1 flu ... for use against it. Researchers at Ohio State University ... virus, which first infected humans during the 1918 pandemic. It ...
... ... beef sold at checkout could help save lives when E. coli outbreaks happen because ... identify the products that are making people sick in order to bring outbreaks under ... ...
... ... has launched an improved web viewer for its flagship Evercore® – Clinical Enterprise Suite ... of the size of the facility. , ... Milwaukee, WI (PRWEB) March 1, 2010 -- TeraMedica Healthcare Technology, ...
... ... in Pharma, Health and Wellness. , ... Philadelphia, PA (PRWEB) March 1, 2010 -- Acknowledging more than 13 ... for specialization, Razorfish has launched Razorfish Health , a dedicated health and wellness ...
... ... ... ... ...
Cached Medicine News:Health News:The proof's in the bubbles 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 3Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 4Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 2Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 3Health News:TeraMedica Unveils Improved Univision, Now Offering a Multi-Layer Enterprise Viewing Platform 2Health News:Razorfish Launches Independent Dedicated Health Brand 2Health News:Razorfish Launches Independent Dedicated Health Brand 3Health News:Razorfish Launches Independent Dedicated Health Brand 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 2Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 3Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 5
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
Medicine Products: